FG001 (ICG-Glu-Glu-AE105)

FG001 is a fluorescent dye injected before brain surgery to make tumor tissue glow under a near-infrared camera. The goal is to help neurosurgeons see the border between tumor and healthy brain in low-grade gliomas and meningiomas, where the boundary is often invisible to the naked eye and the existing dye 5-ALA does not work well. FluoGuide A/S (Denmark) has taken it through a Phase 1 first-in-human dose-escalation study in high-grade gliomas [1] and through an exploratory Phase 2 in head-and-neck cancer [2], with a Phase 2 study in meningiomas and presumed low-grade gliomas registered as NCT06684795 [3]. In February 2026 FluoGuide reported FDA clearance of the IND for FG001 and guided that the first US registration trial would start in Q2 2026 [4].

Investigational only. No FDA clearance, no EMA authorization, no CE-marked diagnostic device registration. A physician cannot order FG001 outside a clinical trial. The trial specifically named in the node data, NCT06684795, targets meningiomas and presumed low-grade gliomas; its status on ClinicalTrials.gov has recently changed to UNKNOWN, which typically means the sponsor has stopped updating the record [3]. That change coincides with the company redirecting effort to a US pathway: FluoGuide reported FDA clearance of the FG001 IND and guided a Q2 2026 registration trial start in its FY2025 annual report [4]. One Phase 1 first-in-human dataset and one exploratory Phase 2 dataset have made it to peer-reviewed publication: a 35-patient malignant glioma dose-escalation study in Neurosurgery 2025 [1] and an oral/oropharyngeal squamous cell carcinoma exploratory Phase 2 in Theranostics 2025 [2]. No CMS coverage decision exists because there is no marketed product to reimburse. FluoGuide A/S trades on Nasdaq First North Growth Market (ticker FLUO) as a micro-cap. Commercial launch in the US would require either a PMA submission (premarket approval, FDA's most stringent device pathway, which requires clinical evidence of safety and effectiveness and typically takes 3 to 5 years) or de novo classification (a faster route for novel low- to moderate-risk device types, but only available when no comparable predicate device is already cleared), alongside a completed registration-quality trial demonstrating clinical utility, not just imaging performance. The specific US pathway FluoGuide will pursue has not been disclosed. No FDA submission number applies at this stage.

FG001 is a two-part molecule. AE105 is a short synthetic peptide (nine amino acids) that binds uPAR, the urokinase plasminogen activator receptor. uPAR is a protein anchored to the outside of cells that helps them chew through the connective tissue around them. Normal brain expresses very little of it. Aggressive tumor cells at the invasive edge express a lot, because breaking down surrounding tissue is how they spread. AE105 is linked via a two-glutamate spacer to indocyanine green (ICG), a near-infrared fluorescent dye that has been in clinical use since the 1950s and is already familiar to surgical teams. In the glioma Phase 1 study the optimized regimen was a single 36 mg IV dose given roughly 16 hours before craniotomy, following a dose-escalation from 1 to 48 mg [1]. In the head-and-neck exploratory Phase 2 patients received 4, 16, or 36 mg the evening before surgery [2]. In the operating room the surgeon shines 780 to 800 nm excitation light on the exposed tissue and views the field through a near-infrared camera. Tumor lights up, healthy brain stays dark. The Neurosurgery glioma study used a Zeiss Pentero surgical microscope with its integrated NIR channel [1]; the Theranostics head-and-neck study used the Stryker Elevision NIR camera system [2]. Both are commercially available NIR-capable platforms with their own FDA clearances for ICG-based imaging, which lowers the platform-integration hurdle for FG001. Sample type is IV administration; there is no external analyte assay. The published data show that FG001 produces measurable tumor-to-background fluorescence contrast at the resection margin on off-the-shelf NIR imaging platforms [1][2]. No head-to-head comparison against 5-ALA has been published.

One Phase 1 first-in-human dataset and one exploratory Phase 2 dataset have been published. Skjoth-Rasmussen et al. in Neurosurgery (2025) enrolled 35 patients undergoing craniotomy for malignant glioma in a dose-escalation Phase 1 study (1 to 48 mg IV, 12 to 17 hours before surgery) and identified 36 mg at ~16 hours as the dose producing the best tumor-to-background ratio [1]. This was a safety, dosing, and imaging-performance study, not a demonstration that using FG001 changed how much tumor was removed or that patients lived longer. Andersen et al. in Theranostics (2025) tested the same compound in an exploratory Phase 2 in patients undergoing surgery for oral and oropharyngeal squamous cell carcinoma (4, 16, or 36 mg the evening before surgery) and showed uPAR-driven contrast between tumor and healthy mucosa [2]. Again, an exploratory imaging trial, not a clinical utility trial. The distinction matters. Analytical validity, meaning the test measures what it claims to measure, is the first hurdle. Clinical utility, meaning using the test changes decisions and improves outcomes, is the harder one, and neither study attempted it. A registration-quality trial in low-grade glioma or meningioma would need to show that patients getting FG001-guided resection have less residual tumor on postoperative MRI, longer progression-free survival, or fewer repeat surgeries than patients getting standard white-light resection. FluoGuide has guided that its first US registration trial will start in Q2 2026 following FDA IND clearance [4], but the study design, endpoints, and site network have not yet been publicly disclosed.

The direct competitor is 5-ALA (aminolevulinic acid HCl, brand names Gliolan in EU, Gleolan in US), approved by FDA in 2017 for fluorescence-guided resection of high-grade gliomas and marketed in the US by NX Development Corp [6]. 5-ALA is a metabolic precursor that tumor cells convert into a fluorescent porphyrin. Reported rates of visible fluorescence in WHO grade II low-grade gliomas vary widely across series, on the order of 10 to 40% depending on grading criteria and camera sensitivity, and 5-ALA is not indicated for meningiomas [5]. That gap is exactly what FluoGuide is aiming at. The addressable US surgical volume is not small: per CBTRUS, meningiomas are the single most common primary CNS tumor at roughly 30,000 to 34,000 new US diagnoses annually, of which a large fraction go to surgery, and diffuse low-grade gliomas add on the order of 4,000 to 5,000 more cases per year [9]. Current fluorescence-guidance penetration in these two indications is effectively zero. Priced in line with other targeted intraoperative dyes (Cytalux and LUMISIGHT are transacted in the low five-figures per dose), a fully penetrated meningioma-plus-LGG opportunity would imply a US TAM in the mid hundreds of millions per year, though realistic near-term uptake would be a small fraction of that. The broader fluorescence-guided surgery field includes On Target Laboratories' pafolacianine (Cytalux), a folate-receptor-targeted dye approved by FDA in 2021 for ovarian cancer and expanded to lung cancer in 2022 [7], and Lumicell's LUMISIGHT (pegulicianin) approved in April 2024 for breast-cancer margin assessment [8]. FluoGuide A/S has no product revenue. Its FY2025 annual report (published February 2026) reported a net loss of DKK 39.5 million (~USD 5.6 million) versus DKK 29.0 million in FY2024, and mid-2025 cash of DKK 19.6 million (~USD 2.8 million); a full year-end 2025 cash figure and an exact current market cap were not extracted here [4]. On a straight-line burn that implies well under a year of runway heading into the planned Q2 2026 registration trial, so a financing (equity raise, debt, or partner deal) is highly likely as a near-term event. No commercial partnership or licensing deal for FG001 has been publicly announced [4]. In competitive terms this is a small challenger with a legitimate scientific angle and a real funding constraint against the execution ahead of it.

The biology is sound and the clinical gap is real. Low-grade gliomas and meningiomas are cases where a surgeon's ability to see the tumor edge in real time directly determines outcomes, and where the existing fluorescence tool does not work reliably. A uPAR-targeted tracer is a rational choice because uPAR expression correlates with tumor invasion at exactly the interface a surgeon cares about. The problem is execution. The Neurosurgery study is a Phase 1 dose-finding, not a Phase 2 efficacy readout, and the only Phase 2 dataset is in head-and-neck, not the CNS indications the company is targeting. NCT06684795 has stopped updating on ClinicalTrials.gov [3], and while the FDA IND clearance and guided Q2 2026 registration trial [4] are meaningful positives, the company is entering that trial as a micro-cap with a rising loss profile and limited disclosed cash, no partner has been announced, and no data have been published comparing FG001 against 5-ALA in the tumor types where 5-ALA fails. The competitive set is also getting more crowded, with pafolacianine expanding to lung and pegulicianin now approved in breast. Check back if FluoGuide actually initiates the US registration trial on the guided Q2 2026 timeline, discloses financing sufficient to complete it, announces a licensing or acquisition deal with a larger CNS or surgical-imaging company, or publishes head-to-head data against 5-ALA in low-grade tumors. Absent one of those catalysts, FG001 is a scientifically interesting agent stuck in an underfunded development program.

Our model estimates a 6% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 13%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by a non-randomized design and its light or open-label blinding; it is held back by the sponsor's thin or weak approval record and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.